Trial intelligence / Profile preview

FOLFIRINOX alone versus FOLFIRINOX followed by chemoradiotherapy for locally advanced inoperable pancreatic cancer

2012-001850-24Phase 2Terminated

Sponsor
Austrian Breast and Colorectal Cancer Study Group
Start
Jul 2012
Modality
Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of irinotecan, fluorouracil, oxaliplatin, folinic acid, capecitabine in pancreatic cancer (PC), sponsored by Austrian Breast and Colorectal Cancer Study Group. Started Jul 2012; status: terminated.

02

Drugs

irinotecanfluorouraciloxaliplatinfolinic acidcapecitabine
03

Conditions

pancreatic cancer (PC)

Beyond the preview

Go deeper on 2012-001850-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-001850-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call